Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Fusion Pharmaceuticals Inc.
Hamilton, Ontario, Canadafusionpharma.com ↗
- Ownership
- Public · FUSN
- Development stage
- Other
01
Overview
Lead program FPI-2265 is in Phase 2 trials for metastatic castration-resistant prostate cancer. The company has developed a platform for targeted alpha therapeutics with proprietary Fast-Clear™ linker technology.
- Therapeutic areas
- Oncology
- Modalities
- Targeted Alpha Therapeutics (TATs)Radioconjugates (RCs)
- Industry
- Biotech
02
Partnerships
AstraZenecaMerck (for evaluating FPI-1434 in combination with KEYTRUDA®)TRIUMFNiowave Inc.BWXT Medical Ltd. (for actinium supply)
Beyond the preview
Go deeper on Fusion Pharmaceuticals Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fusion Pharmaceuticals Inc..